Patients with brain cancer who received this pain medication lived longer, shows the study
It is known that glioblastoma, the type of more aggressive and deadly brain cancer, has a very poor prognosis, but a new study suggests that a medication that cancels pain could extend survival.
Mass Brigham general researchers have found that an already approved medication, an analgesic and anti -vulsers called Gabapentina, has been related to better survival in patients with glioblastoma.
The findings were published in Nature Communications last week.
Michael Bolton had strange symptoms before the diagnosis of brain cancer: “Something is wrong”
Inspired by previous mice studies that showed the potential of gadasopentine in directed tumors, researchers studied the medical results of almost 700 patients with glioblastoma.
Many of them had already been taking Gabapentina to relieve nervous pain, according to a MGB press release.
It is known that glioblastoma, the type of more aggressive and deadly brain cancer, has a very poor prognosis, but a new study suggests that a medication that cancels pain could extend survival. (Istock)
Patients who were taking the medication survived four months more than those who not, 16 months compared to 12 months, described as “statistically significant.”
“Ultimately, our goal was to highlight the emerging role of cancer neuroscience
The breast cancer drug could help prolong survival for children with brain tumors, the study finds
The team was surprised by the survival benefit, Bernstock said.
“It’s always incredible to see that a hypothesis clashes life,” he said. “I was also pleased to see the decrease in serum SSP-1 levels in the UCSF cohort, possibly positioning it as a response biomarker.”
An analgesic and antisivulsion medication called gabapentin has been related to better survival in patients with glioblastoma. (Istock)
According to the initial findings, Bernstock communicated with researchers at the University of California, San Francisco (UCSF) to study more patients with glioblastoma.
Among the 379 patients in USCF, the same result was observed: those who took Gabapentina lived 20.8 months on average, compared to 14.7 months for those who do not take the medication.
“There have been very few advances in survival for patients with GBM since the early 2000s. “
“In both cohorts (1,072 patients in total), the use of gabapentina was constantly associated with a statistically significant improvement in survival,” Bernstock told News Digital.
The researchers also noticed that the Gadasopentina group had lower levels of a protein called TSP-1, which is in the blood serum, a finding that “needs more research.”
The glioblastoma claims the life of around 14,500 Americans every year. The five -year survival rate is only 6.9%. (Istock)
“There have been very few advances in survival for patients with GBM since the early 2000s,” Berstock said in the statement. “We need to think more creatively about emerging biology in these tumors and how to aim them.”
What to know about Gadasopentina
The United States Food and Medicines Administration (FDA) initially approved GADAPENTINA in December 1993 to treat convulsive activity in adults; The approval extended to include children in 2000.
Two years later, the agency approved Gaddapentin for nervous pain after the tiles, according to the agency.
Studies show that the medicine is often prescribed for out of label to treat a variety of pain conditions.
Studies show that the medicine is often prescribed for out of label to treat a variety of pain conditions. (Istock)
Some of the most common side effects of gadasopenin include fatigue, headache, dizziness, fever, nausea and vomiting, memory loss, speaking problems, weight gain, vision problems, movement problems and recurring infections, according to the Cleveland clinic.
Certain medications can interact with gadasopentine. Patients should talk to a doctor if they experience serious or persistent side effects, experts recommend.
Possible limitations and next steps
The study had some limitations, mainly that it is retrospective and was not controlled.
“While the findings are promising, the study is retrospective: patients did not receive gabapentin in a controlled and random way to directly evaluate their effects,” Bernstock told News Digital.
“As such, larger prospective clinical trials are needed to validate these results and investigate the role of Gabapentina and TSP-1 in the GBM progression.”
Click here to register in our health newsletter
Berstock said it is “cautiously optimistic” for the findings.
“While gabapentin is approved by the FDA and generally well tolerated, it is not appropriate to change clinical practice based on these findings only without a controlled study, something in which our collaborators in UCSF are working,” he said.
“It is not appropriate to change clinical practice based only on these findings without a controlled study.”
“That said, in patients with GBM who develop neuropathic pain or seizures after craniotomy, there may be a reason to consider gabapentin more easily than other agents.”
For more health articles, visit www.Newsnews.com/health
Glioblastoma, described by Bernstock as “a relentless and almost universally fatal disease,” is the most common type of primary brain cancer, according to Mayo Clinic.
The disease claims the life of around 14,500 Americans every year. The five -year survival rate is only 6.9%.
Melissa Rudy is a senior health editor and a member of the lifestyle in News Digital. The advice of history can be sent to melissa.rudy@News.com.